↓ Skip to main content

Cochrane Database of Systematic Reviews

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

Overview of attention for article published in Cochrane database of systematic reviews, October 2007
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
97 Dimensions

Readers on

mendeley
112 Mendeley
Title
Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma
Published in
Cochrane database of systematic reviews, October 2007
DOI 10.1002/14651858.cd003805.pub2
Pubmed ID
Authors

Holger Schulz, Julia Bohlius, Nicole Skoetz, Sven Trelle, Thilo Kober, Marcel Reiser, Martin Dreyling, Michael Herold, Guido Schwarzer, Michael Hallek, Andreas Engert

Abstract

Rituximab has been shown to improve response rates and progression free survival when added to chemotherapy in patients with indolent and mantle cell lymphoma. However, the impact of R on overall survival (OS) when given in combination with chemotherapy (R-chemo) has remained unclear so far. We thus performed a comprehensive systematic review in this group of patients to compare R-chemo with chemotherapy alone with respect to OS. Other endpoints were overall response rate (ORR), toxicity and disease control as assessed by measures such as time to treatment failure (TTF), event free-survival (EFS), progression free-survival (PFS) and time to progression (TTP). We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE and conference proceeding from 1990 to 2005. Only randomised controlled trials (RCT) comparing R-chemo with chemotherapy alone in patients with newly diagnosed or relapsed indolent lymphoma and mantle cell lymphoma (MCL) were included. Two review authors extracted data and assessed the study quality. Number needed to treat (NNT) were calculated to facilitate interpretation. Seven randomised controlled trials involving 1943 patients with follicular lymphoma, mantle cell lymphoma, or other indolent lymphomas were included in the meta-analysis. Five studies were published as full-text articles, and two were in abstract form. Patients treated with R-chemo had better overall survival (hazard ratio [HR] for mortality 0.65; 95% confidence interval (CI) 0.54 to 0.78), overall response (relative risk of tumour response 1.21; 95% CI 1.16 to 1.27), and disease control (HR of disease event 0.62; 95% CI 0.55 to 0.71) than patients treated with chemotherapy alone. R-chemo improved overall survival in patients with follicular lymphoma (HR for mortality 0.63; 95% CI 0.51 to 0.79) and in patients with mantle cell lymphoma (HR for mortality 0.60; 95% CI 0.37 to 0.98). However, in the latter case, there was heterogeneity among the trials (P 0.07), making the survival benefit less reliable. The systematic review demonstrated improved OS for patients with indolent lymphoma, particularly in the subgroups of follicular and in mantle cell lymphoma when treated with R-chemo compared to chemotherapy alone.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Australia 1 <1%
Netherlands 1 <1%
Colombia 1 <1%
United States 1 <1%
Unknown 106 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 18%
Researcher 16 14%
Student > Bachelor 13 12%
Student > Ph. D. Student 11 10%
Student > Postgraduate 8 7%
Other 25 22%
Unknown 19 17%
Readers by discipline Count As %
Medicine and Dentistry 50 45%
Nursing and Health Professions 8 7%
Agricultural and Biological Sciences 8 7%
Biochemistry, Genetics and Molecular Biology 4 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 10 9%
Unknown 28 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2018.
All research outputs
#8,098,783
of 12,913,752 outputs
Outputs from Cochrane database of systematic reviews
#8,786
of 10,457 outputs
Outputs of similar age
#97,091
of 190,131 outputs
Outputs of similar age from Cochrane database of systematic reviews
#182
of 213 outputs
Altmetric has tracked 12,913,752 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 10,457 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,131 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 213 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.